🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Changes in Skin Myco- and Microbiome After Lebrikizumab Treatment

Recruitingn/aAges 18 Years - anyAllUniversity Hospital Bispebjerg and Frederiksberg
NCT07807228 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to characterize the skin myco- and microbiome of patients with atopic dermatitis before and after initiation of treatment with lebrikizumab. The main questions it aims to answer are: Does the skin mycobiome change with treatment? Does the skin microbiome change with treatment? Does the abundance of Staphylococcus species change with treatment?

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults ≥18 years diagnosed with atopic dermatitis and initiating treatment with lebrikizumab Exclusion Criteria: * Previous treatment with lebrikizumab * Current treatment with other biologics or JAK-inhibitors * Hypersensitivity to lebrikizumab or any of its constituents * Pregnancy or breastfeeding * Active helminth infection
💊

What it tests

  • Not listed
📍

Where

1 site
Dermatology Department Bispebjerg
Copenhagen, Denmark
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy